Freeline Therapeutics Holdings is a clinical-stage, systemic adeno-associated virus-based gene therapy company. Co.'s pipeline includes programs in the clinic and late-stage preclinical product candidates, as well as research programs targeting applications for systemic gene therapy. Co.'s product candidate, verbrinacogene setparvovec (FLT180a) is intended for the treatment of patients in whom a deficiency of functional clotting Factor IX, causes moderate or severe hemophilia B. Co. is also developing FLT190 for the treatment of Fabry disease, as well as FLT201 and FLT210, for the treatment of Gaucher disease and hemophilia A, respectively. The FRLN YTD return is shown above.
The YTD Return on the FRLN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether FRLN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FRLN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|